LSE · IXI.L
IXICO plc
£0.12£0.00 (0.0%)
IXICO plc’s quoted price sits in the upper half of its reported 52-week range, 9.62% below the high.
Loading market information…
LSE · FAB.L · GBp
Stock price, earnings
Quote as of Oct 29, 2026, 04:10 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Fusion Antibodies plc’s quoted price sits in the lower half of its reported 52-week range, 68.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Fusion Antibodies plc’s next earnings report is currently expected on Dec 7, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Fusion Antibodies plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| £1.04M |
| Q2 2022 | Dec 9, 2022 | -£0.04 | £1.86M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.12£0.00 (0.0%)
IXICO plc’s quoted price sits in the upper half of its reported 52-week range, 9.62% below the high.
£0.09£0.00 (0.0%)
Abingdon Health Plc’s quoted price sits in the lower half of its reported 52-week range, 30.77% below the high.
£0.15-£0.01 (-7.58%)
Sareum Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 61.88% below the high.
£0.19£0.00 (0.0%)
Inspiration Healthcare Group plc’s quoted price sits in the lower half of its reported 52-week range, 42.19% below the high.
£0.28£0.00 (0.0%)
Cambridge Cognition Holdings Plc’s quoted price sits in the lower half of its reported 52-week range, 37.78% below the high.
£0.02-£0.00 (-3.95%)
Genflow Biosciences Plc’s quoted price sits in the lower half of its reported 52-week range, 41.51% below the high.
£0.00-£0.00 (-1.67%)
Aptamer Group plc’s quoted price sits in the lower half of its reported 52-week range, 74.35% below the high.
£0.06+£0.00 (+2.65%)
OptiBiotix Health Plc’s quoted price sits in the lower half of its reported 52-week range, 35.56% below the high.
